efficacy and safety of telavancin in clinical trials a systematic review and meta-analysistelavancin疗效和安全性的临床试验的系统回顾和荟萃分析.pdfVIP

Efficacy and Safety of Telavancin in Clinical Trials: A Systematic Review and Meta-Analysis 1 1 1 1 Konstantinos A. Polyzos , Michael N. Mavros , Konstantinos Z. Vardakas , Marinos C. Makris , Petros I. Rafailidis1,2, Matthew E. Falagas 1,2,3* 1 Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece, 2 Department of Medicine, Henry Dunant Hospital, Athens, Greece, 3 Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts, United States of America Abstract Introduction: The epidemiology and antibiotic resistance of Staphylococcus aureus have evolved, underscoring the need for novel antibiotics, particularly against methicillin-resistant S. aureus (MRSA). Telavancin is a bactericidal lipoglycopeptide with potent activity against Gram-positive pathogens. Objective: To systematically review and synthesize the available evidence from randomized controlled trials (RCTs) evaluating telavancin in the treatment of patients with infections due to Gram-positive organisms with the methodology of meta-analysis. Results: Six RCTs comparing telavancin with vancomycin were included; 4 (2229 patients) referred to complicated skin and soft tissue infections (cSSTIs) and 2 (1503 patients) to hospital-acquired pneumonia (HAP). Regarding cSSTIs, telavancin and vancomycin showed comparable efficacy in clinically evaluable patients (odds ratio [OR] = 1.10 [95% confidence intervals: 0.82–1.48]). Among patients with MRSA infection, telavancin showed higher eradication rates (OR = 1.71 [1.08–2.70]) and a trend towards better clinical response (OR = 1.55 [0.93–2.58]). Regarding HAP, telavancin was non-inferior to vancomycin in terms of clinical response in two Phase III RCTs; m